CIMETIDINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Cimetidine Hydrochloride patents expire, and when can generic versions of Cimetidine Hydrochloride launch?
Cimetidine Hydrochloride is a drug marketed by Dava Pharms Inc, Hospira, Luitpold, Teva Parenteral, Vintage Pharms Llc, Ani Pharms, Chartwell Molecular, Cycle, G And W Labs Inc, Pai Holdings Pharm, Pharm Assoc, and Pharmobedient Cnsltg. and is included in twenty-one NDAs.
The generic ingredient in CIMETIDINE HYDROCHLORIDE is cimetidine hydrochloride. There are twenty-five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the cimetidine hydrochloride profile page.
Summary for CIMETIDINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 12 |
NDAs: | 21 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 57 |
Clinical Trials: | 62 |
Patent Applications: | 794 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CIMETIDINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for CIMETIDINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Assiut University | Early Phase 1 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
Beijing Biostar Pharmaceuticals Co., Ltd. | Phase 2 |
Pharmacology for CIMETIDINE HYDROCHLORIDE
Drug Class | Histamine-2 Receptor Antagonist |
Mechanism of Action | Histamine H2 Receptor Antagonists |